{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:45:07Z","timestamp":1776721507776,"version":"3.51.2"},"reference-count":35,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>OBJECTIVE: To evaluate the type and intensity of response to benralizumab and identify responders and super-responders amongst patients with severe uncontrolled eosinophilic asthma managed in Mexico.\nMETHODS: A multicenter study in 3 hospitals in Mexico evaluating the Asthma Control Test and Asthma Control Questionnaire (ACT) scores; mini Asthma Quality of Life Questionnaire; peripheral blood eosinophils; exhaled fraction of nitric oxide; forced expiratory volume in 1 second before and after benralizumab treatment and the number of exacerbations at 12 months.\nRESULTS: The record of 28 patients with severe uncontrolled eosinophilic asthma were included. At 12-months, 82.1% were considered in asthma control, where 82% were responders and 64% classified as super-responders. 75% of patients had no exacerbations, with ACT scores improvement in 89% and 79% of patients discontinued maintenance corticosteroids. A total of 82% presented forced expiratory volume in 1 second values over 500 ml. ACT scores showed an average decrease of 1.35 points and a statistically significant decrease in serum eosinophils was observed.\nCONCLUSION: This is the first study in Mexico to evaluate the subgroup of super-responders to benralizumab who had clinical, laboratory and quality of life improvements. Besides the vast majority were responders and 64% super-responders at 12-months of treatment.\nKEYWORDS: Benralizumab; Asthma; Asthma Control Test and Asthma Control Questionnaire (ACT); Eosinophils; Exhaled fraction of nitric oxide; Corticosteroids; Quality life.<\/jats:p>","DOI":"10.29262\/ram.v73i1.1562","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:35:40Z","timestamp":1774924540000},"page":"17-25","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders&lt;\/b&gt;","&lt;b&gt;Efectividad real de benralizumab en pacientes mexicanos con asma eosinof\u00edlica grave: respondedores y superrespondedores&lt;\/b&gt;"],"prefix":"10.29262","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2622-1536","authenticated-orcid":false,"given":"Ulises Noel","family":"Garc\u00eda Ram\u00edrez","sequence":"first","affiliation":[{"name":"Instituto Mexicano del Seguro Social (UMAE 1 CMNB IMSS). Le\u00f3n Guanajuato"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-5074","authenticated-orcid":false,"given":"Nadia Karina","family":"Aguilar Hinojosa","sequence":"additional","affiliation":[{"name":"Hospital General Regional 1 Lic. Ignacio Garc\u00eda T\u00e9llez, Instituto Mexicano del Seguro Social, M\u00e9rida, Yucat\u00e1n"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7193-9582","authenticated-orcid":false,"given":"Saraid","family":"Cerda Reyes","sequence":"additional","affiliation":[{"name":"Unidad de Especialidades M\u00e9dicas, Secretar\u00eda de la Defensa Nacional, Naucalpan, Estado de M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3146-5519","authenticated-orcid":false,"given":"Rosa Isela","family":"Campos Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Unidad de Especialidades M\u00e9dicas, Secretar\u00eda de la Defensa Nacional, Naucalpan, Estado de M\u00e9xico."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3073-6604","authenticated-orcid":false,"given":"Nidia Karen","family":"Castill\u00f3n Benavides","sequence":"additional","affiliation":[{"name":"Unidad de Especialidades M\u00e9dicas, Secretar\u00eda de la Defensa Nacional. Naucalpan, Estado de M\u00e9xico.\u00a0"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1660-4784","authenticated-orcid":false,"given":"Jorge Isaac","family":"Velasco Santos","sequence":"additional","affiliation":[{"name":"Hospital Central Dr. Ignacio Morones Prieto, San Luis Potos\u00ed, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-8071","authenticated-orcid":false,"given":"Francisco Javier","family":"N\u00fa\u00f1ez Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital General de Sub-Zona 7, San Francisco del Rinc\u00f3n, Guanajuato, M\u00e9xico.\u00a0"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homero","family":"Garc\u00e9s Flores","sequence":"additional","affiliation":[{"name":"Bachelor's Degree in Basic Biomedical Research, HS Estudios Farmacoecon\u00f3micos, Mexico City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3436-5655","authenticated-orcid":false,"given":"Gustavo Adolfo","family":"Arballo Rivera","sequence":"additional","affiliation":[{"name":"Unidad M\u00e9dica de Alta Especialidad, Centro M\u00e9dico Nacional del Baj\u00edo, Instituto Mexicano del Seguro Social, Le\u00f3n Guanajuato."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2479-3773","authenticated-orcid":false,"given":"Miriam Monzerrat","family":"Flores Razo","sequence":"additional","affiliation":[{"name":"Unidad M\u00e9dica de Alta Especialidad, Centro M\u00e9dico Nacional del Baj\u00edo, Instituto Mexicano del Seguro Social, Le\u00f3n Guanajuato."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5812-4237","authenticated-orcid":false,"given":"Paula Catalina","family":"Lizarazo Guiza","sequence":"additional","affiliation":[{"name":"M\u00e9dico de enlace cient\u00edfico en AstraZeneca M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"66882","doi-asserted-by":"crossref","unstructured":"1. Mendoza-Cano O, Murillo-Zamora E. Assessing the asthma-related burden of disease in Latin American and Caribbean countries: a sociodemographic perspective. Public health. 2024; (227): 163-168.","DOI":"10.1016\/j.puhe.2023.12.016"},{"key":"66883","unstructured":"2. INEGI. [Asthma, a disease related with poor air quality] [Online]; 2021 [cited 2024 04 04. Available from: https:\/\/www.gob.mx\/semarnat\/articulos\/asma-enfermedad-relacionada-con-la-mala-calidad-del-aire"},{"key":"66884","doi-asserted-by":"crossref","unstructured":"3. Venancio-Hern\u00e1ndez M, Mendieta-Flores E, Mendiola-Mar\u00edn J, et a. Abordaje diagn\u00f3stico del asma dif\u00edcil de tratar y asma grave [The diagnostic approach to difficult-to-treat asthma and severe asthma]. Rev Allerg Mex. 2022; (Suppl 1): s94-s111.","DOI":"10.29262\/ram.v69iSupl1.1046"},{"key":"66885","doi-asserted-by":"crossref","unstructured":"4. Reddel H, Bacharier L, Bateman E, et a. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Am J Respir Crit Care Med. 2022; 205 (1): 17-35.","DOI":"10.1164\/rccm.202109-2205PP"},{"key":"66886","doi-asserted-by":"crossref","unstructured":"5. To T, Stanojevic S, Moores G, et a. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012; (12): 204.","DOI":"10.1186\/1471-2458-12-204"},{"key":"66887","doi-asserted-by":"crossref","unstructured":"6. Bakakors A, Loukides S, Usumani O, et a. Biologics in severe asthma: the overlap endotype - opportunities and challenges. Expert Opin Biol Ther. 2020; 20 (12): 1427-1434.","DOI":"10.1080\/14712598.2020.1809651"},{"key":"66888","unstructured":"7. GEMA 5.0. Spanish guideline on the management of Asthma. 2021."},{"key":"66889","unstructured":"8. Larenas-Linneman D, Salas-Hern\u00e1ndez J, Del R\u00edo-Navarro B, et al. MIA 2021, Integrated Management of Asthma: Guidelines for Mexico. Rev Alerg Mex. 2021; 68 (Suppl 1): 122."},{"key":"66890","unstructured":"9. S\u00edvori M, Pascansky D. High T2 severe asthma: analysis of clinical trial design of new biologics. American Journal of Respiratory Medicine. 2022; 22 (1): 98-115."},{"key":"66891","doi-asserted-by":"crossref","unstructured":"10. Quirce S, Phillips-Angles E, Dom\u00ednguez-Ortega J, Barranco P. Biologics in the treatment of severe asthma. Allergol Immunopathol (Madr). 2017; 45 (Suppl 1): 45-49.","DOI":"10.1016\/j.aller.2017.09.012"},{"key":"66892","doi-asserted-by":"crossref","unstructured":"11. Calzetta L, Matera M, Rogliani P. Monoclonal antibodies in severe asthma: is it worth it? Expert Opin Drug Metab Toxicol. 2019; 15 (6): 517-520.","DOI":"10.1080\/17425255.2019.1621837"},{"key":"66893","doi-asserted-by":"crossref","unstructured":"12. Bagnasco D, Heffler E, Testino E, et a. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opin Drug Metab Toxicol. 2019; 15 (2): 113-20.","DOI":"10.1080\/17425255.2019.1568409"},{"key":"66894","doi-asserted-by":"crossref","unstructured":"13. Canonica G, Senna G, Mitchell P, et a. Therapeutic interventions in severe asthma. World Allergy Organ J. 2016; 9 (1): 40.","DOI":"10.1186\/s40413-016-0130-3"},{"key":"66895","doi-asserted-by":"crossref","unstructured":"14. Ridolo E, Pucciarini F, Nizi M, et a. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. Hum Vaccin Immunother. 2020; 16 (10): 2349-56.","DOI":"10.1080\/21645515.2020.1753440"},{"key":"66896","doi-asserted-by":"crossref","unstructured":"15. Pelaia C, Vatrella A, Bruni A, et a. Benralizumab in the treatment of severe asthma: design, development, and potential place in therapy. Drug Des Devel Ther. 2018; (12): 619-628.","DOI":"10.2147\/DDDT.S155307"},{"key":"66897","doi-asserted-by":"crossref","unstructured":"16. Rupani H, Hew M. Super-Responders to severe asthma Treatments: Defining a New Paradigm. J Allergy Clin Immunol Pract. 2021; 9 (11): 4005-4006.","DOI":"10.1016\/j.jaip.2021.08.014"},{"key":"66898","unstructured":"17. Basque-Navarre Society of Respiratory Pathology. svnpar.es. 2018. https:\/\/www.svnpar.es\/wp-content\/uploads\/2018\/11\/Test_ACQ.pdf."},{"key":"66899","unstructured":"18. VADEMECUM. vademecum.es. 2020. https:\/\/www.vademecum.es\/mexico\/medicamento\/1489566\/fasenra-solucion-inyectable-en-jeringa-prellenada-30-mg-ml."},{"key":"66900","doi-asserted-by":"crossref","unstructured":"19. Juniper E, Guyatt G, Cox F, Ferrie P, King D. Development, and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999; 14 (1): 32-38.","DOI":"10.1034\/j.1399-3003.1999.14a08.x"},{"key":"66901","unstructured":"20. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Available from: www.ginasthma.org."},{"key":"66902","doi-asserted-by":"crossref","unstructured":"21. Bakakos A, Rovina N, Bakakos P. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy. Int J Mol Sci. 2021; 22 (8): 3969.","DOI":"10.3390\/ijms22083969"},{"key":"66903","doi-asserted-by":"crossref","unstructured":"22. Larenas-Linnemann D, Gochicoa-Rangel L, Mac\u00edas-Weinmann A, et al. Mexican consensus regarding exhaled nitric oxide fraction in asthma. Rev Allerg Mex. 2020; 67 (Suppl 2): S1-S25.","DOI":"10.29262\/ram.v67i0.760"},{"key":"66904","doi-asserted-by":"crossref","unstructured":"23. Upham JW, Le Lievre C, Jackson DJ, et al. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. J Allergy Clin Immunol Pract. 2021; 9 (11): 3997-4004. doi:10.1016\/j.jaip.2021.06.041","DOI":"10.1016\/j.jaip.2021.06.041"},{"key":"66905","doi-asserted-by":"crossref","unstructured":"24. Miralles-L\u00f3pez J, And\u00fajar-Espinosa R, Bravo-Guti\u00e9rrez F, et a. Analysis of response of severe eosinophilic asthmatic patients to benralizumab. Allergol immunopathol. 2022; 50 (6): 163-168.","DOI":"10.15586\/aei.v50i6.704"},{"key":"66906","doi-asserted-by":"crossref","unstructured":"25. Kavanagh J, Hearn A, Dhariwal J, et a. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. Chest. 2021; 159 (2): 496-506.","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"66907","doi-asserted-by":"crossref","unstructured":"26. Jackson D, Heaney L, Humbert M, et a. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomized multicenter. open-label, phase 4 study. Lancet. 2024; 403 (10423): 271-281.","DOI":"10.1183\/13993003.congress-2023.RCT798"},{"key":"66908","doi-asserted-by":"crossref","unstructured":"27. Pelaia C, Busceti M, Crimi C, et a. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020; (129): 110444.","DOI":"10.1016\/j.biopha.2020.110444"},{"key":"66909","doi-asserted-by":"crossref","unstructured":"28. Vultaggio A, Aliani M, Altieri E, et a. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study. Respir Res. 2023; 24 (1): 135.","DOI":"10.1186\/s12931-023-02439-w"},{"key":"66910","doi-asserted-by":"crossref","unstructured":"29. FitzGerald J, Bleecker E, Nair P, et a. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128-2141.","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"66911","doi-asserted-by":"crossref","unstructured":"30. Bleecker E, FitzGerald J, Chanez P, et a. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomized, multicenter, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115-2127.","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"66912","doi-asserted-by":"crossref","unstructured":"31. Harrison T, Chanez P, Menzella F, et a. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomized, controlled, phase 3b trial. Lancet Respir Med. 2021; 19 (3): 260-274.","DOI":"10.1016\/S2213-2600(20)30414-8"},{"key":"66913","unstructured":"32. Busse W, Bleecker E, FitzGerald J, et a. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019; 7 (1)."},{"key":"66914","doi-asserted-by":"crossref","unstructured":"33. Nair P, Wenzel S, Rabe K, et a. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376 (25): 2448-24-58.","DOI":"10.1056\/NEJMoa1703501"},{"key":"66915","doi-asserted-by":"crossref","unstructured":"34. Menzies-Gow A, Gurnell M, Heaney L, et a. Oral corticosteroid elimination via a personalized reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENT): a multicenter, open-label, single-arm study. Lancet Respir Med. 2022; 10 (1): 47-58.","DOI":"10.1016\/S2213-2600(21)00352-0"},{"key":"66916","doi-asserted-by":"crossref","unstructured":"35. Korn S, Bourdin A, Chupp G, et a. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021; 9 (12): 4381-4392.","DOI":"10.1016\/j.jaip.2021.07.058"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1562\/2836","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1562\/2837","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1562\/2874","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1562\/2836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:57:11Z","timestamp":1776718631000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,30]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v73i1.1562","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"value":"2448-9190","type":"electronic"},{"value":"0002-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}